• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

EML4 Gene Record

  • Summary
  • Interactions
  • Claims
  • EML4 27436 Clinically Actionable

    Alternate Names:

    27436
    ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4
    EML4
    C2orf2
    ELP120
    EMAP-4
    EMAPL4
    ROPP120
    607442
    1316
    ENSG00000143924
    OTTHUMG00000128603
    Echinoderm microtubule-associated protein-like 4
    Q9HC35

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (1 More Sources)

    Gene Categories: Category Details

    KINASE
    CLINICALLY ACTIONABLE

    Publications:

    Lovly et al., 2011, Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors., Cancer Res.
    Kodityal et al., 2016, A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib., Lung Cancer
    Amin et al., 2016, TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors., Oncotarget
    Katayama et al., 2012, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers., Sci Transl Med
    Kwak et al., 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer., N. Engl. J. Med.
    Doebele et al., 2012, Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer., Clin. Cancer Res.
    Singhi et al., 2017, Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma., J Natl Compr Canc Netw
    Yoshida et al., 2016, Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer., J. Clin. Oncol.
    Gainor et al., 2016, Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer., Cancer Discov
    Katayama et al., 2014, Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib., Clin. Cancer Res.
    Shaw et al., 2016, Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F., N. Engl. J. Med.
    Infarinato et al., 2016, The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma., Cancer Discov
    Kim et al., 2013, Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer., J Thorac Oncol
    Sasaki et al., 2011, A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors., Cancer Res.
    Zhang et al., 2016, The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models., Clin. Cancer Res.
    Friboulet et al., 2014, The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer., Cancer Discov
    Ou et al., 2014, Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib., J Thorac Oncol
    Yoshimura et al., 2016, Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells., Cancer Chemother. Pharmacol.
    Tani et al., 2016, Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells., Mol. Cancer Ther.
    Sakamoto et al., 2011, CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant., Cancer Cell
    Zou et al., 2015, PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models., Cancer Cell
    Lovly et al., 2014, Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer., Nat. Med.
    Ardini et al., 2016, Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications., Mol. Cancer Ther.
  • ALECTINIB   EML4

    Interaction Score: 7.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    27009859 28476735 25393796 26849637 27432227 26682573 25228534 21575866 26698910 23344087


    Sources:
    JAX-CKB

  • CHEMBL3397300   EML4

    Interaction Score: 5.68

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    27009859 27432227 25228534 26698910 27780853


    Sources:
    JAX-CKB

  • CRIZOTINIB   EML4

    Interaction Score: 4.83

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26775591 27009859 22277784 20979469 22235099 28476735 27354483 27432227 25228534 26698910 21613408 26554404 23344087 21791641 27780853 24675041


    Sources:
    JAX-CKB

  • ASP-3026   EML4

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    27009859 25228534


    Sources:
    JAX-CKB

  • CERITINIB   EML4

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    26775591 27009859 25173427 27432227 25228534 26698910 27780853 24675041


    Sources:
    JAX-CKB

  • LORLATINIB   EML4

    Interaction Score: 4.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type resistant
    Approval Status Phase I

    PMIDs:
    27432227 26698910 26144315 26554404


    Sources:
    JAX-CKB

  • ENSARTINIB   EML4

    Interaction Score: 3.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    combination therapy Sirolimus + X-396
    Evidence Type Actionable

    PMIDs:
    21613408


    Sources:
    JAX-CKB

  • AFATINIB   EML4

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Afatinib + Alectinib
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    26682573


    Sources:
    JAX-CKB

  • SIROLIMUS   EML4

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Sirolimus + X-396
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    21613408


    Sources:
    JAX-CKB

  • ENTRECTINIB   EML4

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26939704


    Sources:
    JAX-CKB

  • Ensembl: ENSG00000143924

    • Version: 101_38

    Alternate Names:
    EML4 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • JAX-CKB: EML4

    • Version: 27-September-2017

    Alternate Names:
    27436 CKB Entrez Id
    EML4 CKB Gene Synonym
    C2orf2 CKB Gene Synonym

    Gene Info:

    Publications:
    Lovly et al., 2011, Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors., Cancer Res.
    Tani et al., 2016, Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells., Mol. Cancer Ther.
    Amin et al., 2016, TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors., Oncotarget

  • Pharos: EML4

    • Version: 03-September-2020

    Alternate Names:
    Echinoderm microtubule-associated protein-like 4 Gene Name
    Q9HC35 UniProt ID

    Gene Info:

    Gene Categories:
    KINASE

    Publications:

  • FoundationOneGenes: EML4

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: EML4

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21